Takeaway
- In people with type 2 diabetes (T2D) and acute coronary syndrome (ACS), those randomly assigned to ticagrelor had significantly lower rates of major adverse cardiac events (MACE) and mortality.
- Minor bleeding was significantly more common with ticagrelor, but major bleeding was not.
Why this matters
- Guidelines recommend dual antiplatelet...